|
11/03/2022
|
Summary ToggleEledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
|
|
10/24/2022
|
Summary ToggleEledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
|
|
10/03/2022
|
Summary ToggleEledon Pharmaceuticals to Participate in Two Upcoming Conferences
|
|
09/22/2022
|
Summary ToggleEledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
|
|
09/06/2022
|
Summary ToggleEledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy
|
|
08/29/2022
|
Summary ToggleEledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences
|
|
08/11/2022
|
Summary ToggleEledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results
|
|
08/04/2022
|
Summary ToggleEledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
|
|
08/01/2022
|
Summary ToggleEledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
|
|
07/18/2022
|
Summary ToggleEledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation
|
